Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Awareness and perception of fecal microbiota transplantation in Lebanon: a cross-sectional survey among the general population, healthcare workers, physicians, and patients.

Therapeutic advances in gastroenterology·2025
Same author

Evaluation of Antiproliferative Potentials Associated with the Volatile Compounds of <i>Lantana camara</i> Flowers: Selective In Vitro Activity.

Molecules (Basel, Switzerland)·2024
Same author

Dual RNA-seq study of the dynamics of coding and non-coding RNA expression during <i>Clostridioides difficile</i> infection in a mouse model.

mSystems·2024
Same author

Protective Effects of Nettle Tea on SKOV-3 Ovarian Cancer Cells Through ROS Production, Apoptosis Induction, and Motility Inhibition Without Altering Autophagy.

Foods (Basel, Switzerland)·2024
Same author

Spores of Clostridioides difficile are toxin delivery vehicles.

Communications biology·2024
Same author

<i>Clostridioides difficile</i> Flagella.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Jun 17, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K

MicroRNA miR-27a-5p Reduces Intestinal Inflammation Induced by Clostridioides difficile Flagella by Regulating the

Philippe Hussein Kobeissy1,2, Cécile Denève-Larrazet1, Jean-Christophe Marvaud1

  • 1Faculté de Pharmacie, Institut MICALIS (UMR 1319 Université Paris-Saclay, INRAE, AgroParisTech), Equipe Bactéries Pathogènes et Santé, Université Paris-Saclay, Orsay, France.

The Journal of Infectious Diseases
|August 10, 2024
PubMed
Summary

MicroRNA-27a-5p regulates inflammation caused by Clostridioides difficile infection. Overexpressing this microRNA in mice reduced disease severity and intestinal inflammation, highlighting its therapeutic potential.

Keywords:
Clostridioides difficileNF-κBflagellinintestinal inflammationmiR-27a-5p

More Related Videos

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.3K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.5K

Related Experiment Videos

Last Updated: Jun 17, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.3K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.5K

Area of Science:

  • Microbiology
  • Immunology
  • Molecular Biology

Background:

  • Clostridioides difficile causes nosocomial infections, leading to inflammation and diarrhea.
  • C. difficile flagellin FliC activates Toll-like receptor 5 and NF-κB signaling, inducing proinflammatory cytokines.
  • MicroRNA-mediated regulation of FliC-induced inflammation is not well understood.

Purpose of the Study:

  • To investigate the role of microRNAs in C. difficile FliC-induced inflammatory responses.
  • To elucidate the function and therapeutic potential of miR-27a-5p in C. difficile infection.

Main Methods:

  • Analyzed miRNA expression in Caco-2 cells and infected mice using RT-qPCR.
  • Utilized NF-κB inhibitors, miRNA knockdown, and overexpression techniques.
  • Evaluated the therapeutic effect of miR-27a-5p mimic in a mouse model of C. difficile infection.

Main Results:

  • miR-27a-5p was significantly overexpressed in a FliC-dependent manner.
  • NF-κB inhibition reduced miR-27a-5p levels; miR-27a-5p knockdown enhanced NF-κB activation and cytokine production.
  • miR-27a-5p overexpression suppressed inflammation; in vivo treatment reduced disease severity and inflammation.

Conclusions:

  • miR-27a-5p is a key regulator of C. difficile-induced inflammation.
  • miR-27a-5p demonstrates therapeutic potential for managing C. difficile infections.
  • Findings provide insights into novel therapeutic strategies for C. difficile-associated inflammatory complications.